Ovid Therapeutics (OVID) Return on Capital Employed (2017 - 2026)
Ovid Therapeutics (OVID) posted Return on Capital Employed of 27.67% for Q1 2026, up 35.39% on a QoQ basis from 42.82% in Q4 2025, and up 4580.0% year-over-year from 0.59% in Q1 2025.
Ovid Therapeutics (OVID) Return on Capital Employed (2017 - 2026) Analysis & Trends
Ovid Therapeutics' Return on Capital Employed history runs 10 years deep, the most recent figure standing at 27.67% for Q1 2026.
- Quarterly Return on Capital Employed rose 4580.0% year-over-year to 27.67% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27.67% (up 4580.0% YoY) and the FY2025 annual result came in at 37.47%, up 2006.0% from the prior year.
- Return on Capital Employed was 27.67% for Q1 2026 at Ovid Therapeutics, up from 42.82% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 27.67% in Q1 2026 and bottomed at 73.47% in Q1 2025.
- A 5-year average of 51.83% and a median of 48.06% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 10304 bps — and 2026, when it jumped 4580 bps.
- Ovid Therapeutics' Return on Capital Employed stood at 36.27% in 2022, then plunged by 33 bps to 48.17% in 2023, then tumbled by 48 bps to 71.22% in 2024, then jumped by 40 bps to 42.82% in 2025, then jumped by 35 bps to 27.67% in 2026.
- Business Quant data shows OVID's Return on Capital Employed at 27.67% in Q1 2026, 42.82% in Q4 2025, and 64.01% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -107.40% |
| 4 | BeOne Medicines | 472.03 Bn | 467.24 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 122.09 Bn | 114.84 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.99 Bn | 50.80 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 20.34% |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - | -27.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.67% |
| Dec 31, 2025 | -42.82% |
| Sep 30, 2025 | -64.01% |
| Jun 30, 2025 | -58.87% |
| Mar 31, 2025 | -73.47% |
| Dec 31, 2024 | -71.22% |
| Sep 30, 2024 | -70.23% |
| Jun 30, 2024 | -61.54% |
| Mar 31, 2024 | -47.94% |
| Dec 31, 2023 | -48.17% |
| Sep 30, 2023 | -43.67% |
| Jun 30, 2023 | -41.68% |
| Mar 31, 2023 | -37.99% |
| Dec 31, 2022 | -36.27% |
| Dec 31, 2021 | 66.77% |
| Sep 30, 2021 | 63.70% |
| Jun 30, 2021 | 57.41% |
| Mar 31, 2021 | 82.24% |
| Dec 31, 2020 | -131.98% |
| Sep 30, 2020 | -152.63% |